Bosentan Hydrate

波生坦

Report date: 2026/04/12 20:00:13
NMEFirst In Class

Base Information

Drug NameBosentan Hydrate
Drug Alias Name波生坦水合物Bosentanum波生坦一水合物Stayveer全可利 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type B antagonistsEndothelin receptor type A antagonists
TargetsEndothelin receptor type AEndothelin receptor type B
Therapy Area/IndicationsChronic thromboembolic pulmonary hypertensionUlcerFibrosis +[25] 
Global Approved IndicationsUlcerScleroderma, SystemicPulmonary Arterial Hypertension +[4] 
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2001/11/20
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Medical CenterJanssen-Cilag International NvHumanis Saglık Anonim Sirketi +[6] 
Inactive CompaniesHanmi Pharmaceutical Co LtdHeinrich Heine University DusseldorfGeorgetown University +[13] 
Active IndicationsUlcerDiabetes MellitusScleroderma, Systemic +[9] 
Inactive IndicationsChronic thromboembolic pulmonary hypertensionFibrosisDiabetes Mellitus, Type 2 +[16] 

Other Information

ATC CodeC02KX01
Related LinksWikipediaDrugBankKEGG